Condition
Recurrent Mixed Phenotype Acute Leukemia clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Recurrent Mixed Phenotype Acute Leukemia clinical trials that are recruiting, in United States. By phase: Phase 1/2 (3), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 1Country
Newest Recurrent Mixed Phenotype Acute Leukemia clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Decitabine plus FLAG‑Ida chemotherapy and total‑body irradiation before donor stem cell transplant for adults with high‑risk myeloid cancers | Phase 1/2 | Seattle, Washington | Recruiting | Apr 15, 2025 |
| Using a radioactive antibody followed by stem cell transplant to treat high-risk leukemia or myelodysplastic syndrome | Phase 1/2 | Seattle, Washington | Recruiting | Sep 14, 2018 |
| HA-1 TCR T cell therapy for leukemia that returned or didn't respond after a donor stem cell transplant | Phase 1 | Seattle, Washington | Recruiting | Oct 31, 2017 |
| Using radioactive treatment before stem cell transplant for high-risk leukemia patients | Phase 1/2 | Seattle, Washington | Recruiting | Apr 25, 2017 |
All recruiting trials (4)
-
Decitabine plus FLAG‑Ida chemotherapy and total‑body irradiation before donor stem cell transplant for adults with high‑risk myeloid cancers
This test tries whether adding decitabine to FLAG‑Ida chemotherapy and total‑body irradiation before a donor stem cell transplant helps adults with high‑risk or relapsed myeloid blood cancers live longer and stay in remission.
-
Using a radioactive antibody followed by stem cell transplant to treat high-risk leukemia or myelodysplastic syndrome
This study is testing a new radioactive treatment combined with a stem cell transplant to see if it can help people with high-risk leukemia or myelodysplastic syndrome feel better and improve their chances of recovery.
-
HA-1 TCR T cell therapy for leukemia that returned or didn't respond after a donor stem cell transplant
This Phase 1 study will test whether giving specially engineered donor T cells called HA-1 TCR T cells is safe and what dose works for people whose acute leukemia came back or didn't respond after a donor stem cell transplant.
-
Using radioactive treatment before stem cell transplant for high-risk leukemia patients
This study is testing a new radioactive treatment given before a stem cell transplant to see if it can help high-risk leukemia patients by targeting cancer cells while protecting healthy ones.
Related topics
Quick answers
How many Recurrent Mixed Phenotype Acute Leukemia clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in United States. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 3, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.